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1SUMMARY
Part I presents detailed studies on the
incidence of anti-platelet antibodies in immune
thrombocytopenia using a platelet immunofluorescence
method with fluorescein- isothiocyanate
(FITC)-labelled anti-IgG, anti-IgA, anti-IgM and
anti-C3 reagents to characterize the immunochemical
nature of the antibodies detected.
In a series of 85 unselected Chinese patients
(male= 26) female= 59) presenting with
thrombocytopenia (platelet counts: 10-70x109/1.) of
various etiologies, 18 (.18/85 or 21.1%) were found to
have antibodies on their platelets and in their
serum 20 (20/85' or 23.6%), antibodies on their
platelets only and 11 (11/85 or 12.9%) antibodies in
their serum. Attempts to recover the antibodies by
elution procedures were successful in 10 out of 38
cases* with platelets surface-bound antibodies.
Altogether in 49 of the 85 patients (49/85 or 57.6%)
anti-platelet antibodies were detected on their
platelets (membrane-bound) and/or in their serum.
Subsequent studies by testing against
chloroquine-treated platelets revealed that 2 of the
49 antibody-positive patients had antibodies directed
against the shared HLA (Human Leucocyte Antigen)
antigens which are also expressed on
2platelets, and that the other 47, non-HLA antibodies,
i.e. platelet-associated or specific antibodies.
Immunochemical characterization of these
antibodies showed that IgG was detected in 34
patients (34/49) or 69% IgG+ IgM+ IgA in 7
patients (7/49) or 15% IgG+ IgM+ C3 in 1 patient
(1/49) or 2% IgG+ C3 in 3 patients (3/49) or 6% C3
only in 2 patients (2/49) or 4% and IgM only in 2
patient (2/49) or 4%. IgG was identified to be the
dominant immunoglobulin accounting for 92% (45* out of
49 cases) of the sensitizing proteins, followed by
IgM, IgA and Complement (C3) in the-- -49
thrombocytopenic patients with demonstrable
anti-platelet antibodies, a finding in general accord
with those of other reports.
The diagnoses of the 49 antibody-positive
patients were ITP (idiopathic thrombocytopenic
patients- 40 patients to SLE (systemic lupus
erythematosus)- 6 patients, lymphoma- 1 patient and
aplastic anaemia- 2 patients.
As controls, parallel studies on 200 normal
blood donors (male= 100 and female= 100) and 200
pregnant women were performed using identical
methodology and reagents to determine the possible
presence of platelet antibodies in normal subjects
and in pregnant women who are likely to be
alloimmunized to platelet-specific antigens by
previous pregnancies. While no anti-platelet
antibodies•were demonstrated in the 200 blood donors,
326 (26/200 or 13%) of the pregnant women were found
to have IgG-type anti-platelet antibodies which were
identified to be directed against the shared HLA
(Human Leucocyte Antigen) antigens presumably present
on the platelets of the husbands of these women.
The much-reported association between IgG
anti-platelet antibodies and immune thrombocytopenia,
i.e. idiopathic thrombocytopenic purpura (ITP),
systemic lupus erythematosus (SLE) etc., also
occurred in 49 (57.60) of the 85 unselected Chinese
patients with similar disorders. In addition, the
finding of IgM, IgA and C3 (third component-- of
complement) anti-platelet antibodies in 15 patients
suggests, as in other studies, that antibodies of
other immunoglobulin classes and complement also play
a role in the platelet destruction in some of these
patients. The absence of antibodies in the other 36
patients (42.4%) can be attributed to a number of
Eactors such as non-selectiveness of patient sample
and non-availability of platelets in some of the
rases to, demonstrate platelet-membrane-bound
antibodies.
Part II covers the special studies for the
first time, on the frequencies of the **most clinically
significant platelet-specific antigens- the PLA1 and
Baka systems in the Hong Kong Chinese.
From a series of 100 male and 100 female
Chinese blood donors, the PLA1 antigen was found to
4be present on the platelets of all of them, i.e.
PLA1-100% positive, and the Baka antigen was present
in 184 only, i.e. Baka- 92% positive. This findings
differ significantly (p= 0.0305 for PLA1 and p=
0.0241 for Baka) from those reported in the American
and European (Caucasian and Black) populations
studies, indicating that platelet-specific antigen
frequencies like their counterparts on red and white
blood cells can vary because of racial differences.
The fact that the 200 Chinese blood -donors
were all found to be PLA1 positive is of considerable
clinical importance, because this would mean----- a
complete absence of PLA1 negative individual in the
population. Since-most cases of alloimmune neonatal
thrombocytopenia and post-transfusion purpura are due
to the platelet anti-PLA1 antibodies in the Caucasian
PLA1* negative individuals, the non-occurrence of
these two allo-immune thrombocytopenic disorders in
the Chinese can thus be attributed to their being
100% PLA1 positive! On the other hand, alloimmune
neonatal thrombocytopenia and post-transfusion
purpura involving 'other platelet specific antigen
systems, such as the Bak system can occur in the
local Chinese as 8% of them have been found to be
Baka negative in this study. However, the incidence
of alloimmune thrombocytopenic disorders caused by
anti-Baka antibodies is very low even in the
Caucasians (Baka antigen positive frequency As 90.1%
- TABLE 1) since, so far, only a few cases has been
reported (30, (34).
5INTRODUCTION
Platelets are essential for the formation of a
primary haemostatic plug in the maintenance of
haemostasis following injury to the blood vessel
wall, and alterations to their numbers or function
will affect the dynamic balance of the system.
Therefore a marked decrease in the total number of
circulating platelets or thrombocytopenia is often
associated with a bleeding tendency which can be
life-threatening.
The role played by platelet-antibodies in the
accelerated destruction of circulating platelets
leading to an often severe clinical condition known
as immune thrombocytopenia is well recognised and has
been the subject of a large number of investigations
in Europe and America (1), (2), (3) & (4). Immune
thrombocytopenia is defined as a destructive platelet
disorder associated with cell-bound antibodies
(immunoglobulins) or complement on the platelet
surface or unbound antibodies in the serum. The
disorder may be classified into three major groups as
being caused by:-
(1) allo-antibodies- produced against
platelet-specific antigens or HLA antigens
(Human Leucocyte Antigen), following
transfusion or transplacental
6immunization, resulting in:-
(a) Decreased post-transfusion survival of
platelets
(b) Alloimmune neonatal thrombocytopenia
(c) Post-transfusion purpura.
(2) auto-antibodie! againstproduce
platelet membrane antigens resulting in:-
(a) Idiopathic thrombocytopenic purpura
(ITP)
(b) Autoimmune thrombocytopenia associated
with other autoimmune diseases e.g.
systemic lupus erythematosus (SLE):
autoimmune thyroiditis rheumatoid
arthritis, etc.
(3) drug-induced antibodies- immune-complex
absorption inresulting drug-induced
thrombocytopenia.
For the detection of antibodies to platelets,
a variety of methods have been developed. Technical
details and- a critical analysis of these methods are
given in a recent publication (5).
In Hong Kong, the immune thrombocytopenia
resulting from cell-bound auto-antibodies- i.e.
idiopathic thrombocytopenic purpura (ITP) is a
relatively common platelet disorder affecting both
children and adults. But because tests for
anti-platelet antibodies have not been available in
7the local hospitals, the diagnosis of this disorder
is made by exclusion only. The author is thus
prompted to investigate the incidence of
anti-platelet antibodies in local Chinese patients
presenting with thrombocytopenias suspected of being
immune mediated and to compare the results obtained
with those from studies on Caucasian patients with a
view to assess the clinical significance, if any, of
the findings.
The method to be used for this study is the
Platelet Immunofluorescence Test (6) which is
selected because the technique is adaptable for the
antibody types that occur in different clinical
situations and is sensitive enough to detect these
antibodies in low concentrations in serum and on the
cell surface. Moreover, using fluorescein
isothiocyanate (FITC)-labelled anti-IgG, anti-IgA,
anti-IgM and anti-C3, makes possible the study of the
immunochemical nature of the antibodies. Although
only semiquantitative, the platelet fluorescent
method is widely used for demonstrating platelet
antibodies (7).
Platelets possess platelet-specific antigens
in addition to the shared antigens with leucocytes
(Human leucocyte antigen or HLA) and red cells (8).
These include the P1A, K0, P1E, Bak, Lek$ DUZO
systems. The frequencies of platelet-specific
antigen distributions in the European and North
8American populations have been extensively studied
and reported (9). Most of the antibodies for
defining these antigens were from the sera of mothers
of infants with alloimmune neonatal thrombocytopenia
or of persons receiving multiple platelet
transfusions. In this part of the world, on the
other hand, while the Japanese, in recent years, have
been making steady progress in their effort to
determine the platelet-specific antigen frequencies
in their population (10), similar information from
the Chinese is sadly lacking even though one-tenth of
the world populations today belongs to this race--!-----It
is therefore the intention of the author to combine
the investigation on the 'incidence of antiplatelet
antibodies in immune thrombocytopenia with a special
study on the gene frequencies of platelet-specific
antigen in the local Chinese. The reason for
undertaking this special study is two-fold firstly,
to seek the missing information on the frequency of 2
of the important platelet-specific antigens among
Chinese which should be of value in anthropology as
well as in medicine, and, secondly, to confirm the
hypothesis that alloimmune neonatal thrombocytopenia
and post-transfusion purpura, relatively common in
the Caucasians, are virtually absent in the Chinese
because of difference in the frequencies of the
clinically important, PLAT platelet-specific antigen
between the two racial groups.
9LITERATURE REVIEW- IMMUNE THROMBOCYTOPENIA
Immune thrombocytopenia as defined by KELTON
et al (2) is a destructive thrombocytopenic disorder
associated with increased level of immunoglobulins or
complement on the platelet surface and includes any
disorder in which platelets coated with
immunoglobulins are removed from the circulation by
the reticulo-endothelial system resulting in
thrombocytopenia.
WATERS et al (11) classify the immune
thrombocytopenia into three major groups,--- which
overlap in certain disease states:
a) Alloantibodies
1. Decreased post-transfusion survival of
platelets
2. Alloimmune neonatal thrombocytopenia
(ANT)
3. Post-transfusion purpura (PTP).
b) Autoantibodies
1. Idiopathic thrombocytopenic purpura
(ITP)
2. Autoimmune thrombocytopenia associated
with other disorders.
c) Drug-induced antibodies
1. Drug absorption mechanism
2. Immune complex and autoantibody
mechanism.
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The usual indicator of alloimmunization is
taken to be the presence of alloantibodies directed
against the corresponding antigens. In the case of
platelets, the alloantigens consist of those
exclusive to the platelets (platelet-specific
antigens) and those shared with other cells, of the
latter, the HLA antigens (antigens shared with
leucocytes) are important in the immunological
aspects of platelet transfusion therapy (12), (18),
(19). The platelet-specific alloantigens, on the
other hand, are involved in immune thrombocytopenia
of the neonate and in post-transfusion- purpur-a-,
Recent studies have indicated that several of these
specific antigens, e.g. PLA1 (Zwa), KOb, Baka etc.,
are located on the platelet membrane glycoproteins
IIIa and IIb (20), (21). HYDE et al recently
demonstrated that platelet antigens. are variably
expressed on the plasma membranes of megakaryocytes
at various stages of maturation (22).
The gene and phenotype frequencies of the
platelet specific alloantigens in Caucasian
populations which have been well defined and reported
(23) are shown in TABLE I. and TABLE 2 shows the
reported frequencies of the clinically important PLA1





in the Caucasian Populations
Gene Phenotypic
System Antigen frequency frequency
PLA P1A1 0.854 97.6
p1A2 0.145 26.8.
KO KOa 0.0745 14.3
KOb 0.9255 99.4
pIE pIE] 0.975 99.9
PIE2 0.025 5.0
Bak Baka 0.685 90. 1
Lek Leka 98.2
DUZO DUZO 0.094 22.2
Data from Central Laboratory of Netherlands Red
Cross Blood Transfusion Service
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TABLE 2
Reported frequencies of PLA1 (9) (10)
Country n* 070 PLA1+ Reference
Great Britain 1983 98.24 (110)
West Germany 1211 97.85 (111)
France 289 97.58 (112)
Netherlands 287 97.65 (23-)
Europe (8 centres) 98 (113)
Canada 1143 98.17 (1.14-)--
USA 452 97 (8)
USA 46 95.65 (115)
USA/whites 250 96.80 (9)
USA/blacks 243 99.59 (9)
Japan 300 100.00 (10)
Hong Kong/Chinese 200 100.00 present study
Number of subjects tested.
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RECOGNITION OF THE OCCURRENCE OF
IMMUNE THROMBOCYTOPENIA
(a) ALLOANTIBODIES
(1) Decreased post-transfusion survival of
platelets- The prophylactic use of platelet
transfusions in marrow-suppressed patients has
reduced the incidence of haemorrhage in severe
thrombocytopenic patients (17). At the same time,
the number of platelet transfusions given to an
individual patient has increased. As a consequence,
long-term replacement therapy to these patients often
results in alloimmunization of recipients to random
donor platelets with the development of
alloantibodies to the HLA antigens (antigens shared
with leucocytes) or platelet-associated or specific
antigens (18), (19) (24). The presence of these
antibodies causes a decreased post-transfusion
survival of platelets due to their rapid
destruction. The incidence of alloimmunization to
the HLA antigens is in the range of 50-70% (25),
(26), while that due to the platelet-specific
antigens is about 25% (27). Once alloimmunized,
these patients become refractory to subsequent
platelet transfusions and may present a complication
in their management.
(2) Alloimmune neonatal thromboc to e nia (ANT)
First described by MOULINIER (28) is a
self -limiting disease of neonates analogous to Rhesus
haemolytic disease of the newborn (HDN). The
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platelets of the fetus are destroyed by IgG
alloantibody produced by the mother in response to a
fetal platelet-specific antigen of paternal origin.
Unlike HDN, alloimmune neonatal thrombocytopenia
frequently occurs in the first pregnancy in 0.1-0.2%
of live birth (8). The antiplatelet antibody
involved is almost always anti-PLA1 from a PLA1
negative mother (29), though very rarely, the
antibody responsible can be anti-Baka produced by a
Baka negative female (30). The disease is manifest
early with signs of bruising and bleeding which can
be life-threatening. Thrombocytopenia in the newborn
may also be caused by the passive transplacental
transfer of antiplatelet autoantibodies from a mother
with idiopathic th rombocyt ope ni c purpura (31).
(3) Post-transfusion purpura (PTP)- In this
syndrome, profound thrombocytopenia develops about
2-12 days after a transfusion, in association with
the presence of antiplatelet alloantibodies.
VAN LOGHEM et al reported the first case in
1959 (32) but it was SHULMAN et al (33) who pointed
out that there must be a connection between the
immunization to the platelet antigen and the onset of
thrombocytopenia. Most patients have been female and
PLA1 negative with a prior history of blood
transfusion or pregnancy. The patient's serum.
contains a potent anti-PLA1 antibody of IgG type.
The severe thrombocytopenia is due to destruction of
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patient's own PLAT negative platelets by an unknown
mechanism. One hypothesis proposed is that the
transfused PLA1 positive platelets release PLA1
antigen which is absorbed by the patient's own PLA1
negative cells, making them targets for the anti-PLA1
antibody or part of an immune complex (33).
Recently, a few cases of post-transfusion purpura
involving the Bak system (Baka) has been reported
(34).
(b) AUTOANTIBODIS
Idiopathic thrombocytope nic purpura (ITP)
VERLHOLF in 1735 (35) is attributed to be the
first to describe the clinical syndrome of idiopathic
thrombocytopenic purpura (ITP), a disorder of unknown
aetiology characterised by a reduced peripheral
platelet count, increased megakaryocytes in the bone
marrow and a shortened platelet lifespan. But
KRAUSS, in 1883, appears to be the first to associate
the haemorrhagic symptoms with thrombocytopenia
according to DAMESHEK et al (36). Among early
descriptions of the disorder are those of FRANK (37)
and MINOT (38), and reviews by others can be found in
the more recent literature e.g. (39), (40), (13).
For many years it was suspected that
thrombocytopenia in some patients might result from
antibody-induced destruction of platelets, albeit
evidence was lacking. The observation that transient
thrombocytopenia occurred in infants born to mothers
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with idiopathic thrombocytopenic purpura (ITP)
suggested that the platelet disorder was caused by a
humoral factor capable of crossing the placenta
(41). HARRINGTON et al (42) confirmed this
hypothesis by infusing plasma from affected patients
into healthy non-thrombocytopenic volunteers (himself
included) and observing an immediate drop in their
platelet counts which returned to normal several days
later. Subsequently, MCMILLAN et al (43) reported
the detection of increased amounts' of
platelet-associated IgG (anti-platelet antibodies) in
patients with ITP and related conditions, thereby
showing that the factor in the plasma was IgG, a
finding consistent with the placenta-crossing ability
of the immunoglobulin (44). However, the first study
to indicate that an autoimmune mechanism might be the
underlying factor for ITP was reported in 1982.
Using an immunofluorescent technique, VAN LEEUWEN et
al (45) demonstrated IgG antiplatelet antibodies in
their ITP patients' plasma (14 of 42) and in the
eluates prepared from their platelets (35 of 42) the
latter gave a positive reaction with normal platelets
but not with platelets from patients with Glanzmann's
thrombasthenia. Since thrombasthenic platelets have
a marked reduction or absence of membrane
glycoproteins (GP) IIb and IIIa (46), these authors
suggested that ITP patients may produce platelet
autoantibodies (membrane-bound) directed against
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these glycoproteins. BORNE et al defined the
characteristics of the antiplatelet autoantibodies
(membrane-bound) in ITP (47), showing that in 95% of
the patients, IgG antibodies were demonstrable either
alone (72%) or in combination with IgM, IgA or both.
In 5%, only IgM was detected. It has been reported
by HAUCH et al (48) and CINES et al (49) that
platelet-bound C3 (third component of complement) is
increased in ITP. Studies by MYERS et al (50) and
FREEDMAN et al-.. (51) confirmed the presence of C3 in
their ITP patients. Therefore, most of the workers
concluded that not only IgG but also antibodies of
other immunoglobulin classes and complement may play
a role in platelet destruction in some of the ITP
patients (52). On the other hand, PANZER et al (53)
reported that although increased levels of IgG (66%),
IgM (75%), IgA (44%) and C3 (29%) were found in 76%
of their patients with ITP, increased amount of these
immunoglobulins and complement were also observed in
some patients with presumed non-immune
thrombocytopenias (e.g. bone marrow aplasia or
malignancy, septicemia, hypersplenism and cirrhosis
of liver). They therefore concluded that their data
indicated the evaluation of neither parameter alone
nor the combination of platelet antibodies (IgG and
other immunoglobulins) and complement C3 would
discriminate between immune and non-immune
thrombocytopenia.
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In addition, platelet antibodies causing
thrombocytopenia may often be associated with
autoimmune diseases, such as systemic lupus
erythematosus (SLE), autoimmune thyroiditis,
rheumatoid arthritis (47), (15) and autoimmune
haemolytic anaemia (Evan's syndrome) (16).
Autoimmune thrombocytopenia has also been reported in
patients with chronic lymphocytic leukaemia, lymphoma
(54) and solid tumours (55). Most of these patients
demonstrate high levels of antiplatelet antibodies.
(c) DRUG-INDUCED ANTIBODIES
It was the work of SHULMAN that provided the
first in vitro evidence to support the theory that
drug-induced immune thrombocytopenia is an immune
complex disease (56). The theory was further
supported by the investigation of KELTON et al who
reported that most drug-induced platelet disorders
are immune mediated, but are not caused by auto- or
alloantibodies (57).
The two established mechanisms of in vivo
platelet destruction by drug-induced antibodies are:-
(1) Drug absorption. MURPHY et al (58)
reported that treatment with high dose penicillin
could result in immune thrombocytope ni a due to the
absorption of the drug onto the cell surface as in
penicillin-induced haemolytic anaemia (59). The
presence of the offending drug is required in the in
vitro testing system for the cell-antibody
interaction.
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(2) Immune-complex mechanism. Thrombo-
cytopenia involving quinine and quinidine has been
well-defined and the antibody identified as being
complement-fixing IgG (60). The recent study by
LEEUWEN et al (61) showed that F (ab) 2 fragments of
the quinine/quinidine antibody did not react with
platelets in vitro in the presence of the drug,
suggesting that the Fc part of the antibody is
essential for attachment of the immune complex to the
platelets through the latter's Fc receptor.
Moreover, they also confirmed the observation of
KUNCKI et al (62) that platelets from patient with
Bernard-Soulier syndrome lack receptor for
drug-dependent antibodies by demonstrating that
platelet membrane glycoprotein Ib (absent in
Bernard-Soulier platelets) was the receptor for these
antibodies.
A vast number of other drugs have been
reported to cause immune thrombocytopenia (63). In
many instances, the relationship may be
coincidental. Drugs like Sedormid (64) and
sulphonamides (65) have been convincingly shown by in
vivo and in vitro testing to operate through an
immunological mechanism.
LABORATORY METHODS FOR THE INVESTIGATION OF
IMMUNE THROMBOCYTOPENIA
Following the demonstration by HARRINGTON et
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al (42) that the infusion of plasma from patients
with idiopathic thrombocytopenic purpura (ITP) caused
thrombocytopenia in normal individuals, many attempts
have been made to develop reliable and sensitive
methods for the detection of platelet allo- and
autoantibodies both in the serum and directly on the
platelets of patients with immune thrombocytopenia
(39).
Thus, in the decade since DIXON et al (66)
first documented elevated levels of platelet
surface-bound IgG in ITP patients, a variety of
methods has. been reported (47), (49),- (67) - (72).
Each depends on one of the following: inhibition by
platelets of a reaction that is dependent on IgG
antigenic determinants (66), (73) incubation of
platelets with antihuman IgG labelled with either
radioactive isotopes 125I, or an enzyme (49), (68),
(69) reaction of platelets with Staphylococcal
protein A (74), or radial immunodiffusion. of
solubilized platelet-associated IgG into agar
containing -anti-IgG (72). The platelet-associated
IgG (PAIgG) is quantitated by comparison with known
amounts of purified human IgG. In addition,
qualitative methods using antihuman globulins and
complement reagents labelled with fluorescent dyes
have also been developed (47).
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A major criticism of the different
quantitative methods for platelet-associated IgG
(PAIgG) is that they are detecting not only platelet
autoantibody, but also non-specifically bound
immunogl obul i ns and immune complexes and
intracellular platelet proteins (75), (76)$ (77).
Estimates of platelet-associated IgG (PAIgG) can be
increased by platelet fragmentations (78). However,
a recent method has overcome this problem by
excluding fragments from the platelet preparati-on and
using 125I-labelled monoclonal antihuman globulin
reagents (7.9).
The platelet immunofluorescence test described
by BORNE et al (6) avoids, to a large extent, the
problems of non-specific binding by employing
paraformaldehyde-fixed platelets (77). Moreover, as
the test is read by examination of a platelet
suspension using fluore.scent microscopy, platelet
fragments can be seen and excluded. Although
possibly less sensitive, and only semi-quantitative,
the platelet immunof luore scent method is widely used
not only for demonstrating platelet autoantibodies in
patients with idiopathic thrombocytope nic purpura
(ITP) (6) but also for detecting platelet
alloantibodies in alloimmune neonatal thrombo-
cytopenia (30), (80), post-transfusion purpura (33),
(34) and in platelet compatibility testing for
patients who are refractory to random platelet
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transfusion (81). In two recent surveys of
anti-platelet antibody detection conducted by the
United Kingdom (U.K.) Platelet and Granulocyte
Serology Working Group for laboratories in the U.K.
and Eire (7), (82), it was found that the platelet
immunofluorescent test and the platelet enzyme-linked
immunosorbent assay were the most commonly used
techniques, and that there were no apparent
differences in performance between assays using these
two methods (69). As pointed out by MCMILLAN (13),
this semi-quantitative test may be more adaptable to
routine laboratory use since it requires no
sophisticated equipment or expensive reagents.
As indicated above, methods for detection of
antibodies to platelets are extremely diverse. New
techniques are constantly being introduced which
reflect a general dissatisfaction with the available
methods, since no one technique can satisfy the basic
requirements of being simple to perform, sensitive,
specific, quantitative and adaptable for the
detection of both serum and platelet-bound
antibodies. However, inspite of the shortcomings
inherent in these methods, it has been suggested that
platelet antibody testing is essential in the
investigation of immune thrombocytopenia, as a
possible guide to prognosis and treatment (11). The-
appearance of numerous related publications in the
literature within the last two decades not only
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supports this suggestion but, at the same time,
confirms the rightful place the test has in a modern
clinical laboratory.
For the busy clinical pathology laboratories
in Hong Kong, it is sensible to adopt a technique
that can be performed routinely, requiring no
sophisticated equipment or expensive reagent, yet
sensitive enough to provide the relevant information
to the clinicians. Such a technique, as noted in the
recent UK Platelet and Granulocyte Serology Working
Group Surveys is either the platelet
immunofluorescence test or the platelet enzyme-linked
immunosorbent assay (7), (82). These two techniques
have the further advantage of being suitable for use
in platelet-crossmatching to improve post-transfusion
platelet survival in alloimmunized patients.
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MATERIALS AND METHODS
Source of Blood Samples
(1) Patients
The studies on the incidence of antiplatelet
antibodies in immune thrombocytopenia described in
this thesis were performed on clotted blood samples
and, whenever available, on anticoagulated blood
samples with dipotassium salt of ethylenediamine
tetra-acetic acid (EDTA- 1.2 mg/ml blood) received
for testing in the Department of Morbid Anatomy's
Research Laboratory at the Prince of Wales Hospital,
Shatin. Special arrangements with the Paediatric
Units at the Princess Margaret Hospital (Lai Chi
Kok), the Queen Elizabeth Hospital (Kowloon) as well
as the Medical Unit, the Paediatric Unit and the Li
Ka Shing Specialist Clinic at the Prince of Wales
Hospital were made for referring specimens from their
patients suffering from immune thrombocytopenic
disorders.
Thus, a total of 85 unselected Chinese
patients (male=26 female=59 ranging in ages from 2
days to 80 years) presenting with thrombocytopenia
(platelet counts at the time of testing varied from
10- 70 x 109/1) were studied. The clinical
diagnoses as shown in TABLE 5 included idiopathic
thrombocytopenic purpura, 70 patients systemic lupus
erythematosus, 8 patients lymphoma, 2 patients
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aplastic anaemia, 3 patients and suspected
drug-induced thrombocytopenia, 2 patients.
Although the clinicians were requested to
collect both clotted and anticoagulated (EDTA) blood
samples from each patient. at the time of initial
diagnosis of immune thrombocytopenia but,
regrettably, the request for two blood samples was
not always complied with. Thus, clotted and EDTA
blood specimens were received from only 61 patients
and, for the other. 24 patients, only clotted blood
were received.
(2) Chinese blood donors
The EDTA blood samples used in the
platelet-specific antigens phenotyping studies and in
the preparation of group '0' platelet suspensions
were collected from Chinese blood donors at the Hong
Kong Red Cross Blood Transfusion Centre, and so were
the blood samples for platelet antibodies screening
in normal subjects.
(3) Pregnant women
The clotted blood samples used for detection
of alloimmunisation to platelet-specific and/or HLA
antigens' as a result of fetal-maternal
incompatibility were obtained from 200 pregnant women
at their first attendance of the Antenatal Clinic at
the Prince of Wales Hospital. However, the obstetric
histories including parity of these women were not
available initially.
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Many of the blood samples tested were received
by special delivery, either as clotted blood or in
EDTA anticoagulant. Sera were separated from clotted
blood samples and stored at -20°C until test, while
EDTA blood were processed immediately for platelets
and tests carried out on the same day of receipt as
far as possible.
Source of Reagents






Anti-C3 all these reagents were from
DAKOPATTS, Copenhagen, Denmark.
Optional dilutions for use were determined by
titration as described under Methods.
(2) Positive control serum:
Serum- containing multi-specific anti-HLA
antibodies was obtained from BEHRING
DIAGNOSTIC, West Germany.
(3) Platelet-specific antigens typing sera:-
Anti-PLAT (Zwa) and anti-Baka sera were gifts
from:-
(1) Dr. A. von dem Borne,
Netherlands Red Cross Blood Transfusion
Service, Amsterdam, The Netherlands.
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(2) Prof. A.H. Waters,
Department of Haematology, St.
Bartholomew's Hospital Medical College,
London, England.
Both antisera were obtained from multiparous
PLAT negative and Baka negative women who have
been immunized by previous pregnancies.
4) Normal group 'AB' serum:-
A mixture of 4 sera from Chinese male group
'AB' donors, freshly collected and kept at
-70°C.
Standard Solutions
,1) Phosphate-buffered saline (PBS), pH 7.2
NaCl 8.2 g. (140.2 mM)
Na2HP04.2H20 1.6 g. (9.0 mM)
NaH2PO4.2H20 0.2 g. (1.3 mM)
Distilled water to 1,000 ml
(2) EDTA-buffer solution pH7.2
Na2HP04.2H20 3.13 g. (17.6 mM)
Na2ED.TA 3.33 g. (9.9 mM)
NaCl 9.0 g. (153.8 mM)
Distilled water to 1,000 ml
l) blllA-bovlne serum aloumin (EDTA-BSA) Solution
EDTA-buffer solution with 0.2% (w/v) bovine
serum albumin (BSA). To be prepared shortly
before use from a 30% w/v stock solution of
BSA (Commonwealth Serum Laboratories,
Melbourne, Australia).
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(4) Paraformaldehyde solution (6)
Stock solution: 4% w/v paraformaldehyde in
PBS. To dissolve the paraformaldehyde, the
mixture was heated to 70°C and held for a few
minutes. 1M NaOH was added, dropwise with
mixing until solution cleared. The stock
solution was stored at 4°C, protected from
light.
Working solution: The 4% stock solution was
diluted..1 :4 in PBS and the pH, adjusted if
necessary, to 7.3 with 1M/HC1. The solution
was stable for up to 2 weeks when kept at 4°C
protected from light.
(5) Chloroquine solution, pH 5.0 (83) (85)
Freshly prepared 20% chloroquine diphosphate
salt (200 mg/ml in phosphate buffered saline)
and adjusted pH to 5.0 before use.
Methods
No originality is claimed for any of the
platelet serology methods used by the author in the
studies presented in Part I and Part II of this
thesis. The tests were mostly those described by
BORNE et al (6). The methods can be conveniently
classified as:-
Part I:
(i) Preparation of group '0' platelet
suspension
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(ii) Platelet immunof luore scence techniques:
(a) Indirect test for platelet
antibodies (auto or allo) in the
serum from clotted blood
(b) Direct test for surface-bound
(auto) antibodies on the platelets
from EDTA blood
(c) Elution of surface-bound (auto)
platelet antibodies (84)
(d) Determination of the optimal
dilution of FITC-labelled
anti-globulin reagents
(e) Differentiation' between HLA
antibodies and platelet- specific*
antibodies.
Part II: (i) Preparation of platelets suspension for
platelet specific antigens typin
(ii) Immunof luore scence test for
platelet-specific antigens typing.
Part I (i) Preparation of Group lot platelets
suspension
3 normal blood group '0' donors'
samples in EDTA anticoagulant were
centrifuged at low speed for 10 minutes
at 200 g. (Group '0' blood was used to
avoid the interferance by anti-A and/or
anti-B antibodies in the donor's
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serum). The supernatant platelet-rich
plasma was removed and washed three
times with EDTA-buffer solution. After
each washing by centrifugation at 1000
g. for 5 minutes, the platelets were
thoroughly resuspended. Then the
well-washed platelets were fixed in 3
ml. of 1% freshly prepared
paraformaldehyde solution for 5 minutes
at room temperature- this step was
necessary to prevent non-specific
fluorescence of the platelets (5).
After fixing, the platelets were washed
twice as before and suspended at a
concentration of 250- 400 x 109/1 in
EDTA-BSA buffer solution. The platelet
suspension was now ready for use as
'target' platelets in the indirect
immunofluorescence test.
(ii) (a) Indirect test for platelet
antibodies (allo or auto) in the
patients' serum from clotted blood
0.1 ml. of group '0' platelet
suspension was added to 0.1 ml. of
patient's serum in plastic test-
tubes (7 x 50 mm.) and incubated for
60 minutes at 370C (anti-human
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globulin, anti-IgG, anti-IgA and
anti-C3) or at room temperature for
IgM. (For detection of C3 or
complement-binding, further addition
of 0.1 MI. of fresh AB serum
followed by another- 30 minutes'
incubation at 370C was required.)
The platelets were then washed
three times (centrifuged at 1000 g.
for 5 minutes after each wash) using
EDTA-buffer solution. After
removing the last wash supernatant,
0.1 ml. of appropriate FITC-labelled
anti-globulin reagent, suitably
diluted in PBS was added and the
platelets left at room temperature
for 30 minutes. The mixture was
then washed twice as before. 0.05
ml. of glycerol PBS (3 part
glycerol:l part PBS) was added to
the platelet button which, after
careful mixing, was placed on a
slide under a cover-slip. The
preparations were examined with a
fluorescent microscope using a X40
objective and epifluorescent U.V.
illumination.
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Results were scored from negative
(-) through graded positives i.e.,
intensity of fluorescence (W+, 1+,
2+, 3+, and 4+). Different patterns
of positive reactions given by
anti-IgG, anti-IgA, anti-IgM,
anti-C3 as shown in TABLE 3 were
indicative of presence of platelet
antibodies (allo or auto) in the
patient's serum.
As negative and positive controls,
normal AB serum and multi-specific
ILA serum were similarly tested
against the group '0' platelet
suspension using the same method as
iescribed above.
(b) Direct test for surface-bound (auto)
antibodies on patient's platelets
from EDTA blood
A direct test was done on the
patient's platelets. Owing to
thrombocytopenia, the test was only
possible when the platelet count was
above 20 x 109/1. The patient's
platelets were prepared in exactly
the same way as those of the group
'0' donors, including fixation in 1%
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TABLE 3
Appearance of Positive Reactions
in the Platelet Immunofluorescent Test*
Antiglobulin Appearance of Positive
Class
Anti-IgG Overall increase in cell fluorescence
Anti-IgA
with bright, well-defined points of
fluorescent beading on the surface
and .especially the peripheral of
the cell.
Anti-IgM Large number of well-defined points
of fluorescence over the whole cell-
not confined to the periphery of the
cell. Little increased cell
fluorescence.
Anti-C3 Increased cell fluorescence. The
points of beading on the cell
periphery coalesce to form an
unbroken ring of fluorescence
around the cell.
(* Reproduced from Minchinton, R.M. Waters, A.H. (1982).
Detection and clinical significance of platelet and
granulocyte antibodies. Broadsheet No. 1, Aust. Inst.
Med. Lab. Sci.)
(Attempts to produce actual photomicrographs for illustration
from colour slides of positive cases were unsuccessful.)
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paraformaldehyde solution and
adjusting to a concentration in this
circumstance, of about 0.5 x 109
platelet s/1.
0.1 m1, of the a ppropriate
FITC-labelled anti-immunoglobulin
reagent was added to 0.1 ml. of the
patient's platelet suspension in a
plastic test tube (5 x 70 mm.). A
negative control of FITC-labelled
anti-immunoglobulin added to group
'0' platelet suspension is also put
up in another tube. After mixing
and incubation for 30 minutes at
room temperature in the dark, both
tubes were washed twice in
EDTA-buffer solution (as above).
0.05 ml. of glycerol-PBS (3 part
glycerol+ 1 part PBS) was added to
the platelets which after mixing
were placed on glass slides under
cover slips. The preparations (test
and control) were examined with
fluorescent microscopy as described
in (a) the indirect test. A
positive reaction in the test
preparation only, showed
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presence of surface-bound (auto
antibodies on the patient'
platelets.
(c) Elution of surface-bound (auto)
platelet antibodies (84)
This was a modification of the
method described for red cells by
RUBIN (80). Platelets from the
patient's EDTA blood which had been
found positive in the direct. test
were washed and suspended in
EDTA-BSA buffer solution -to a-- f-ina-l
concentration of 0.5 x 109
platelets/l. 1' volume of this
suspension was mixed with 2 volumes
of ether and shaken vigorously for 2
minutes. The mixture was incubated
for 30 minutes at 37°C in a
waterbath and shaken frequently.
After centrifugation of the mixture,
three layers were found: the stroma,
ether and the eluate, which was
removed with a pipette. The
presence of surface-bound platelet
antibodies in the.. eluate was
confirmed by testing against group
'0' platelet suspension as in the
indirect test.
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(d) Determination of the optimal
dilution of FITC-labelled
antiglobulin reagents
To establish the optimal
dilution, the anti-immunoglobulin
reagents were tested in a
chequerboard titration (TABLE 4).
Dilutions of the labelled
antiglobulin reagents were made in
PBS, ranging from 1/10 to 1/100. A
selection of two sera known to be
positive for platelets were used to
set up a chequerboard titration.
The optimal dilution was the highest
dilution which gave a clear negative
control and good 2+ to 3+ positivity
with the antisera. All diluted
anti-globulin reagents were
centrifuged at 2000 g. for 10
minutes to sediment particulate
fluorescent debris. Dilution of the
reagents in PBS was only prepared
and used on the test day to avoid
reduction in potency.
(e) Differentiation between HLA
antibodies and platelet-specific
antibodies (83) (85)
The well-washed platelet pellet
prepared from 5 ml. of group 0'
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TABLE 4
Chequerboard Titration for Anti-immunoglobulin Reagents
Antiglobulin Dilution
1/10 1/20 1/30 1/40* 1/50 1/60 1/70 1/80 1/90 1/100Antiserum
EtA 3+ 3+ 3+ 2+ 2+ 2+ 2+ 2+ 1+ 1
Multispecific (1
HIU 3+ 3+ 3+ 3+ 2+ 2+ 2+ 2+ 1+ 1+
Multispecific (2)
Negative Control
* Optimal dilution 1/30- 1/40
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platelet rich plasma was suspended
in 5 ml. fresh chloroquine solution
and incubated in the dark at room
temperature for 2 hours with
occasional mixing. The suspension
was then washed 3 times in EDTA
buffer, fixed in 1% paraformaldehyde
solution and used in the indirect




antibodies because of the removal of
the HLA antigens on platelets by
this treatment (86), a positive
reaction would indicate the presence
of platelet-specific antibodies.
Part II (i) Preparation of platelets suspension for
platelet specific antigens typing
The method used was exactly the same
as that described for preparation of
group '0' platelets suspension (Part
I-i).
(ii) Immunof luore scence test for
platelet-specific antigens typing
Again, the methods used for
platelet-specific antigens typing was
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exactly the same as that described for
indirect test for platelet antibodies in
the patient's serum (Part I-a).
However, instead of testing patient's
serum against donors' platelet
suspensions, 200 blood donors' platelets
suspensions were typed against the 2
antisera known to react with platelets
carrying the PLAT and Baka antigens..
Thus, positive reactions would indicate
the presence of PLAT and Baka antigens
on the blood donors' platelets. To rule
out false positive results due to
surface-bound (auto) antibodies, each of
the 200 blood donors platelets were
tested simultaneously by the direct test
(Part I-b) which served as negative
controls. Typing results were only
accepted as valid when all the direct
tests were negative.
The racial frequencies of PLA1 and
Baka between the Chinese blood donors
and the Caucasians (published data in
TABLE 1) were compared statistically
with Fisher's exact test (87). Gene
frequencies were derived from the-
Hardy-Weinberg equilibrium for two.
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alleleles and calculated according to
MOURANT et al (88). The confidence




Part I- Platelet Antibodies
Eighty-five unselected Chinese patients (Male
= 26 Female= 59) presenting with severe
thrombocytopenia (pl'atelet counts: 10-70x109/1 of
various diagnoses (TABLE 5) were studied.
As can be seen from TABLE 6, positive Platelet
Immunofluorescence Test results (graded from 1+ to
4+) were obtained in 49 (Male= 12 Female= 37) out
of the 8S patients (57.60). A breakdown of the 49
platelet-antibodies positive patients reveals that 18
(18/85 or 21.1%) had antibodies on their platelet
surface membranes (i.e., platelet-bound
autoantibodies) by the direct test and in their serum
by the indirect test 20 (20/85 or 23.S%)) had
antibodies on their platelet surface membranes only
(i.e., platelet-bound autoantibodies) 11 (11/85 or
12.9%) had antibodies in their serum. Attempts to
elute the platelet-bound autoantibodies were
successful* in 10. of the 38 positive patients as shown
by testing the eluates against normal donor platelets
in the indirect test as shown in TABLE 7. The lower
rate of success in the elution study was partly due
to the difficulty of obtaining adequate numbers of'
platelets for testing in the severely
thrombocytopenic patients and partly due to.
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TABLE 5
Clinical Diagnoses of the 85 Patients
Diagnose No. Studied
1. Idiopathic thrombocytopenic 70
purpura (ITP)
82. Systemic lupus erythematosus (SLE)
3. Lymphoma 2
4. Aplastic anaemia 3
S. Thrombocyt ope ni a? drug induced 2
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TABLE 6
Test Results with Polyspecific Anti-Globulin Reagent
in 85* Thrombocytopenic Patients
Patient's Patient's serum No. of %







61*- Both patient's serum platelets available
for study
24*- Only patient's serum available for study
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TABLE 7
Elution of Platelet-Bound (Auto-) Antibodies
in the 38 Patients with Positive Direct Tests
Result of the
Indirect Test on Eluate
No. of
patients tested No. negativeNo. positive
38 10 28
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insufficient EDTA blood samples( 2 ml.) received to
prepared platelet suspension for the elution
procedure.
Platelet antibodies found in the 49 patients
were further studied with monospecific FITC-labelled
.anti-immunoglobulin reagents as well as
anti-complement component C3 for immunochemi:cal
characterization. The results as indicated in TABLE
8 were:- IgG only in 34 cases (69%) IgG+ IgM+ IgA
in 7 cases (15%) IgG+ IgM+ C3 in 1 case(2%) IgG+
C3 in 3 cases (6%) C3 only in 2 cases (4%) and IgM
only, 2 cases (4%).
Specificity studies on the platelet antibodies
were also conducted by testing against
chloroquine-treated and untreated normal donors
platelets (83). It was observed that except for the
2 patients with aplastic• anaemia whose platelet
antibodies were found to be directed against the
shared HLA antigens expressed on platelets, the
others (N=47) were non-HLA antibodies, i.e.,
platelet-associated or specific antibodies (TABLE 9)
directed towards ill-defined platelet surface
,antigens- determinants on membrane glycoprotein (GP)
IIb and IIIa (41).
As shown in TABLE 10, the clinical diagnoses
and relevant data of the 49 thrombocytopenic patients
found to have antibodies on their platelets and in
their serum included (a) idiopathic thrombocytopenic
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TABLE 8
Reaction patterns with mono-specific anti-immunoglobulin
reagents and complement in the 49 patients
with positive platelet-antibodies tests










Platelet antibodies studies using cells prepared
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Clinical Diagnoses of the
49 Platelet-Antibodies Positive Patients
Diagnoses No. positive
1. Idiopathic thrombocytopenic 40
purpura (ITP)




purpura (ITP), N=40 (40/70) (b) lupus erythematosus
(SLE), N=6 (6/8) (c) lymphoma, N=l (1/2) and (d)
aplastic anaemia, N=2 (2/3).
During the same time, the author tested
platelet samples from 200 normal blood donors (Male=
100 and Female= 100) and serum samples from 200
pregnant women as controls using identical techniques
and reagents. While no free allo-antibodies or
platelet-bound autoantibodies were detected in these
normal blood ..donors, evidence of alloimmunization due
to previous pregnancies were demonstrated in 26
(26/200 or 13%) pregnant women (who were subsequently
found to be multiparous) by the presence of IgG type
anti-HLA allo-antibodies in their serum samples
(TABLE 9).
Part II- Platelet-Specific Antigens
Platelet suspensions prepared from the EDTA
samples collected from 200 Chinese blood donors (Male
= 100 Female= 100) were each phenotyped for the
clinically. important platelet-specific antigens of
the PLA and Bak systems. The phenotyping results and
the calculated frequencies are presented in TABLES 11
and 12 from which it can be seen that all the 200
Chinese blood donors carried the PLA1 antigen (or
100% PLA1 positive) in other words, there was no
PLA1 negative phenotype among them. The Baka
antigen, however, was found to be absent on-16 of the
50
donors (16/200), indicating that the Baka positive
frequency was 92% in the Chinese samples tested. The
frequency of the PLA1 gene was found to be 1.000 and
of the Baka gene 0.718, with a lower 95% confidence
limit of 0.998 (PLA1) and 0.925 (Baka). These
frequencies were significantly different from those
of the Caucasian populations (p=0.0305 for PLA1
antigen and p=0.0241 for Baka antigen).
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TABLE 11
Results of Typing for Platelet-Specific Antigen
200 samples of platelets from Chinese blood donors
were typed for PLAT and B.aka antigens.
N= 200




Platelet-Specific Antigens in Hong Kong Chinese
N= 200
System Antigen Phenotypic Gene
frequency frequency*
P1A P1A1 100 1.00
P1A2 0 0.00
Bak Baka 92 0.718
* Gene frequencies were derived from the
Hardy-Weinberg formula for-two allele system.
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DISCUSSION
Part I- Platelet Antibodies
it is generally accepted that immune
thrombocytopenia occurs with high levels of
platelet-associated immunoglobulins and complement in
the form of surface-bound autoantibodies or unbound
antibodies in the serum (2), (3), (4). Such
antibodies were demonstrated on the platelets and in
the sera of 49 Chinese patients from an. unselec-ted-
group of 85 clinically diagnosed cases of immune
thrombocytopenia, thus confirming their immune
nature. This is of importance as it is the first
such study that has been conducted in the Hong Kong
Chinese. The overall positivity rate of 57.6%
(49/85) when compared with the 75% and 83% positive
results from studies by other investigators (47),
(53) appears to be low, if the type of test samples
used (i.e., whether. patient's platelets or serum is
tested) is ignored. Both these groups of
investigators (47), (53) used patients' platelets on
every case, while in the current study, only
patients' serum had to be used in those cases where
only clotted blood samples were received (TABLE 6),
and the low positivity rate is most likely due to
this. The observation of KELTON et al (90) that
there are some patients with immune thrombocytoenia
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with increased surface-bound immunoglobulins on the
platelets but little unbound immunoglobulins free in
the serum, may support this reasoning.
The successful elutions of surface-bound
platelet antibodies (IgG-immunoglobulin) from 10 of
the 38 patients with positive direct tests (TABLE 6)
demonstrate the autoantibody nature of the
surface-bound IgG in immune thrombocytopenia,
particularly idiopathic thrombocytopenic purpura
(ITP) (94).
The findings of IgG alone as the dominant
immunoglobulin on the platelets and in the seta of 34
patients (69%) and in combination with IgM and IgA
and/or C3 in 49 patients (92-1.-) (TABLE 8) are, on the
whole comparable with the ranges reported by other
investigators (47), (53), (93).
Besides the predominance of IgG
immunoglobulin, the demonstration of platelet
antibodies of the IgM class, IgA class,-and C3 (third
component of complement) is in accord with that of
several groups of investigators who reported that
many patients with active immune thrombocytopenia
e.g. ITP had increased amounts of different classes
of immunoglobulins and complement on their platelets
(47), (91), (92).
The presence of increased levels of. IgG, IgM,
IgA and complement (C3) in some patients with
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presumed non-immune thrombocytopenias (e.g.
hyperspleni sm and septicemia) as reported by PANZER
et. al (59) is not observed in the current study.
None of the 49 antibody-positive patients'
thrombocytopenias can be classified as non-immune
according to the clinical findings (TABLE 10). It is
also consistent with the findings of other
investigators (15), (49) that platelet antibodies are
demonstrable not only in patients with idiopathic
thrombocytopenic purpura (ITP) but also in those with
immune mediated secondary, thrombocytopenias
associated with systemic lupus erythematosus- -{S-L--E)
lymphoproliferative disease and aplastic anaemia.
In the entire series. of 85 suspected immune
thrombocytopenic patients studied, the largest group
was the 70 patients with clinically diagnosed ITP
(70/85 or 82.3%). The incidence of platelet antibody
positivity in this group was 40/70 (57.1%) while
antibody-positivity was also observed in the 9 of the
other 15 patients with secondary thrombocytopenias.
It is therefore appropriate and relevant to
consider the 'significance of the findings in these
ITP patients in conjunction with their clinical data
thereby to assess.. whether any correlation can be
established between platelet antibodies and immune
thrombocytopenias, especially -ITP.
As shown in TABLE 13, the 70 ITP patients
were divided into groups (a) n=35 (Male=14,
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TABLE13 THE 70 Patients Diacrosed as ITB
Sex Treatment Patients' Platelet-Antibody TestsPlatelet
count
Croup Age X109/1 Bone. mattowetc.Pdurition Positive results/No restedrange TotalSplenectosryP Steroids No.
of PatierPlatelets Ser Platelets Serom
16/35 16/35
2 days Normal or increased
wesskaryocytes with 2/35<3/12(a) 14 10- 50 immature foras. No No (cord serum)(n-35) 35No sarrow infiltration
No splenomegaly





33- 6/12 4 50- 65 Yes Yes (H-3) 7/7 7/7(n-7) 35 yrs. 7
15/28 11/28 4/28
15











Female=21) (b) n=7 (Male=3, Female=4) and (c) n=28
(Male=8, Female=20). As observed by other
investigators, there was a predominance of female
over male patients with a ratio of 1.8:1. The
platelet counts of these patients showed variations
at the time of testing between the 3 groups. The
diagnosis of ITP was arrived at by the clinical
presentations and laboratory findings, viz, easy
bruising, petechiae, no splenomegaly, persistent
thrombocytopenia normal coagulation profile normal
or increased bone marrow megakaryocytes with some
immature forms and absence of marrow infiltration.
Group (a) consists of 35 patients-- 18
antibody-positive (16 were positive on platelets and
negative in serum 2 were positive in cord serum) and
17 antibody-negative (only serum were tested). The
disease duration of these patients varied from 2 days.
3 months when first seen by the doctors at the
clinics, and none had received treatment at the time
of testing. Of the 16 antibody-positive (on
platelets only) patients, 1 (a male aged .25 years)
was found to have a positive Coombs test when
investigated for suspected autoimmune haemolytic
anaemia (AIHA) as well as persistent
thrombocytopenia. These findings confirmed that his,
was a' case of Evan's Syndrome (16), i.e., AIHA and
ITP. Both disorders could have been caused by -a
single autoantibody directed against a common red
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cell-platelet antigen. The 2 patients with
positive-antibody tests in cord serum were neonates
born by 2 ITP mothers (in gorup C) in whom
transplacental passage of IgG autoantibodies was
responsible for their transient neonatal
thrombocytopenia. They were therefore not only the
youngest (aged 2 days) among the 85 patients in this
study, but were also classical examples of
thrombocytopenia in the newborn caused by
placenta-crossing IgG autoantibodies from mothers
with ITP (31), (41), (42). The finding of antibodies
on the platelets of the 16 patients (16/33)
countscorrelates with their very low platelet'
(10-51x109/1), and indicates an acute phase of the
disorder. Hence the thrombocytopenia could be
attributed to an accelerated platelet destruction
mediated primarily by, IgG platelet antibodies the
presence of which explain the predominance of IgG
immunoglobuilin found in 92% of the 49
antibody-positive patients with immune
thrombocytopenia (TABLE 8). The in vivo survival
experiments of RIES et al (95) and KERNOFF et al (96)
demonstrating that platelets from ITP patients coated
with high levels of IgG antibodies show shorter
survival time or greater hepatic destruction can be
quoted to support this hypothesis. One improtant
observation from the test-results of the 16
antibody-positive patients (16/33) was the finding of.
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antibodies on their platelets only but not in their
serum, which seems to indicate that in the acute
phase of ITP all the autoant ibod ie s produced are
absorbed onto the platelet membranes leaving no
unabsorbed (unbound) antibodies free in the serum to
give a positive test. Similar observation was
reported by KELTON (90). Thus, it is obvious that a
proper platelet-antibody test for ITP patients
especially in the acute phase should include tests on
both the platelets 'and the serum since a single test
on the serum alone may not reflect the true ant_ibod.y_._.
status of the patient. For this reason, the 17
patients (17/33) found negative for platelet
antibodies when only their serum *were tested would
need re-appraisal in view of their clinical
presentations as well as their marked
thrombocytopenia which favour the diagnosis of acute
ITP with 'presence of autoantibodies on *their
platelets if not-in their serum.
Group (b) consists of 7 patients-- all
positive on the paltelets and in the serum- with
persistent, thrombocytopenia (50-65x109/1) inspite of
treatment with corticosteroids and splenectomy (3/7)
over a period of 3 to 6 months. They were considered
to be refractory to treatment or were in relapse
following induced remission. It has been observed
that responses to corticosteroids therapy are
indicated by a rapid rise in platelet count above the
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normal range and a gradual fall in platelet
antibodies (49), (66) while responses to splenectomy
are followed by a rapid increase in platelet counts
postsurgery as well as an acceleratd reduction in
platelet antibodies due mainly to the removal of an
important site of antibodies production (3), (13).
These 7 patients, however, happened to be
non-responding to the steroids treatment and
splenectomy (3/7) with a positive antibody level
still on their platelets and in their serum.
Group (c) consists of 28 patients
antibody-positive (all were positive on platelets but
only 11/28 positive in the serum), and 13
antibody-negative (10 were negative on both platelets
and serum 3 were negative when only serum were
tested)-- with a disease duration of longer than 6
months. All had been treated with corticosteroids
and 11 of them, splenectomized (1 in China and said
to have received treatment with traditional Chinese
herbal medicine for thrombocytopenia before coming to
Hong Kong). The 15 antibody-positive, treated
patients were no.t unlike those 7 antibody-positive
and treated patients in group (b) with the exception
that their ITP were of a longer duration. Their
antibody-positivity as well as their thrombocytopenia
were indications of a resistance to the steroids
treatment and splenectomy (1/15). They were now
probably in the chronic phase of ITP with variable
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presence of platelet antibodies on the platelets or
in the serum. In contrast, of the 13
antibody-negative patients, 10 had undergone
splenectomy and 3 had been on corticosteroids therapy
before the commencement of this study. The
antibody-negativity was probably the results of the
steroids treatment in the 3 only serum tested
patients (if it could be assumed that their platelets
would also be negative at this stage) and the removal
of an important antibody-production site- the spleen
(13) in the other 10 patients. Thus, their negative
findings could be accepted as possible signs of
partial remissions with steroids and particularly
splenectomy induced immuno'suppression. However,
their platelet counts (TABLE 13) were still below the
expected levels for a normal response to steroids or
splenectomy and the reason for this is obscure.
In common with other studies of this nature,
the testing for platelet antibodies was performed
only once in each ITP individual it remains,
therefore, to be elucidated by further studies,
whether the platelet antibodies wax and wane
following treatments with corticosteroids,
splenectomy and or immunosuppressants in those
antibody-positive ITP patients (97). However,
whatever the outcome, the result of. the analysis on.
the clinical data of the 70 ITP patients appears to*
show a correlation between the platelet antibodies
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and ITP. In addition, the usefulness of the
platelet-antibody t'e'st as an important adjunct to the
diagnostic measures for immune thrombocytopenia is
proven in this study.
Besides the ITP patients, the other 9 platelet
antibody-positive patients with secondary
thrombocytopenias also presented interesting* clinical
data (TABLE 14) that warrant further discussions.
Thus the findings of platelet antibodies in 6 SLE
patients (6/8) examplify that platelet antibodies are
one of the common autoant ibod ie s produced. in SLE
These SLE patients were still antibody-positive
inspite of corticosteroids therapy.
The thrombocytopenia in the lymphoma
(Hodgkin's) patient who had been treated with
radiotherapy was puzzling because no explanation
could be found for the sudden onset of
thrombocytopenia (platelet count: 40x109/1). The
bone marrow aspirate and biopsy showed only increased
megakaryocytes and no infiltration. Splenomegaly was
absent.. The demonstration of anti-platelet
antibodies was very rewarding in this case. Such
thrombocytopenias usually resolve with steroids
treatment or. splenectomy, as had been in the 6
similar cases reported by COHEN (98) who concluded
that ITP in lymphoma- a rare occurrence of no
prognostic significance- does not necessarily imply
recurrent or active malignancy. Follow-up
information was lacking in this patient.
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TABLE-- Clinical Diagnoses Data of the 9 Platelet Antibody- positive Patient
14 with Immune Mediated Secondary Thrombocytopenias Aplastic Anaemia
Disease duration Drug treatmentPlatelet count SplenectomyDiagnoses Bone marrow picture, etc
(X109/1)
SLE, n=6 25- 66 Corticosteroids Not availableNo1 year





35-70 Corticosteroids No Hypoplastic.Aplastic, n=2 2 years
and regular transfusions No foreign cells.anaemia
with whole blood and
platelet concentrates
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The 2 patients with aplastic anaemia with
platelet anti-HLA alloantibodies (TABLES 9 & 10) had
been transfused regularly with whole blood and
platelet concentrates because of bone marrow
aplasia. The development of platelet anti-HLA
alloantibodies with the resultant poor survival of
transfused platelets from random donors is a typical
example of alloimmunization to the foreign HLA and
platelet specific antigens present on the donors
platelets (99)., (100), (101).
Since the early 1970s when platelet-rich
plasma and platelet concentrates prepared from random
donors first became available in Hong Kong, platelet
transfusions- have been. used extensively as standard.
.treatment for bleeding thrombocytopenic patients in
our regional and teaching hospitals. If the reported
incidences of alloiminunization to the HLA antigens
and platelet-specific, antigens in the range of 50-70%
(25), (26), and 25% (27) respectively are used to
predict the appearance of refractory state in our
thrombocytopenic patients on long term
platelet-support, it would be reasonable to expect
that, at least, half- of them will become
alloimmunized similar to the 2 aplastic anaemia
patients in this study, resulting in unsatisfactory
post-transfusion platelet increments..
Alloimmunization to platelet antigens, HLA or
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platelet-specific, however, can be delayed, but not
avoided, by minimizing the patient's exposure to
these antigens using leucocyte poor blood products-
red cells and/or platelets- from the beginning of
treatment and performing platelet crossmatching tests
to select compatible donors for alloimmunized
patients (102), (24). The platelet immuno-
fluorescence test (6) used extensively in the current
study, can be conveniently employed for this purpose.
The complete absence of platelet antibodies in
the 200 normal blood donors included as controls,
confirms- the specificity and sensitivity of the
technique used in this study. In contrast, the
detection. of IgG anti-HLA antibodies in the 26
pregnant women indicates that they must have been
alloimmunized by previous pregnancies against fetal
leucocyte antigens (HLA) of paternal origin as their
obstetric histories reveal that they were all
multiparous and had never received any, blood
transfusions. The observation that HLA antibodies do
not have- any harmful effect on the fetus (26), (103),
is upheld in this study since all the 26 HLA
antibody-positive pregnant women subsequently gave
birth to normal babies without showing any symptoms
of suffering from alloimmune neonatal
thrombocytopenia.
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Part II- Platelet-Specific Antigens
The value of red cell blood groups in
anthropology was foreshadowed by the finding of
HIRSZFELD et al (104) of differences in the
distribution of ABO groups amongst various national
armies. Many surveys were subsequently undertaken
not only on red cells (88), but also on leucocytes
(105) and this type of studies became widely accepted
in ethnology. Today, while the distributions of red
cell antigens and leucocyte antigens (HLA)• of the
world's various races including the Chinese are
well-known and the author can rightly claim to be one
of the first to study and report on the distribution
of the major red cell blood group systems in Hong
Kong Chinese (106), (107), studies on distributions
of the platelet-specific antigens have so far been
confined to the Caucasian populations (23) and
recently, the Japanese (10).
The principal interest of study of this nature
is the comparison of the findings with those in other
countries. In this regard it must be emphasized the
author's group is not a homogeneous one. It could
not be. said that the subjects tested represent a
segregated population or that they are a random
selection of the Hong Kong Chinese.
The most striking feature of the finding. in
this study is the complete absence of PLA1 negative
individuals among the 200 Chinese blood donors
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tested. In other words, they are 100% positive for
the clinically important platelet-specific PLA1
antigen in contrast with the 97.6% of PLA1 positive
frequency of the Caucasian populations in Europe and
North America (TABLE 2) where alloimmune neonatal
thrombocytopenia (25), (27), (28), and
post-transfusion purpura (29), (30) attributed to
alloimmunization of the 2.4% PLA1 negative
individuals by pregnancy on platelet transfusion are
relatively common. The finding, therefore, offers a
possible explanation to the non-occurrence of the two
PLA1-related alloimmune thrombocytopenic disorders
(25), (27), (28), (108) in the Hong Kong Chinese.
However, this does not mean that alloimmune
thrombocytopenic disorders caused by antibodies of
other platelet-specific antigens, e.g. antigens of
the Bak system, cannot occur, because 8% of the local
Chinese population lack the Baka antigen, and are the
likely candidates for alloimmunization through
pregnancy or platelet transfusion. On the other
hand, if the reported incidence of Baka related
alloimmune thrombocytopenias in the Caucasian
populations can be taken to indicate the
immunogenicity of this platelet specific antigen
(Baka), then the chance of its occurrence in the Hong
Kong Chinese is rare because even with a Baka
negativity of 10% in the Caucasians (TABLE 1). so
far, only two cases of alloimmune neonatal
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thrombocytopenia and post-transfusion purpura caused
by anti-Baka antibody have been reported (30, (34).
Since similar findings of 100% of PLAT
positivity in the 300 Japanese blood donors was
recently reported by SHIBATA et al (1*0), it makes the
author wonder whether there is, after all, an iota of
truth in the legend that the Japanese people are
and his 6,000descendants of Chu Fu （ 徐 福 ）
followers (3)000 boys and 3,000 girls) who were sent
inby the First Emperor of the Qin （ 秦 始 皇 帝 ）
the 28th year of his reign (BC219) to look for
elixirs in the East Seas and never returned! (109)
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CONCLUSIONS
Part I- Platelet Antibodies
Platelet antibodies of IgG, IgM, IgA1.
immunoglobulin classes and complement C3 are
found In the majority of Chinese patients with
immune thrombocytopenia using the platelet
immunof luo re sce nce technique. The incidence of
positive rate is 57.1% (40/70) in patients with
idiopathic thrombocytopenic purpura (ITP).
Platelet antibodies are also demonstrable on
patients with secondary thrombocytopenia such as
systemic lupus erythematosus, lymphoma and
aplastic anaemia. Therefore,. the testing for
platelet antibodies in patients with clinically
suspected immune thrombocytopenia, particularly
ITP, can be helpful to clinicians in these
situations for confirming the diagnosis.
Platelet-anitbody tests should be performed on
both platelets and serum from the patient, to
ensure reliable results.
Hong Kong Chinese multiparous pregnant women are2.
susceptible to alloimmunization to the HLA
antigens due to fetal-maternal HLA
incompatibility. However, maternal platelet IgG
anti-HLA antibodies appear to have no harmful
effect on the fetus.
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3. Absence of antibodies on the platelets of 200
normal blood donors confirms the specificity of
the immunof luore sce nce test employed.
4. Patients with aplastic anaemia or leukaemia-on
long-term platelet supportive therapy from
random blood donors are susceptible to
alloimmunization by the foreign HLA (Human
Leucocyte Antigens) and platelet-specific
antigens on the donor platelets. Once
alloimmuni,zed, the appearance of HLA and/or
platelet specific antibodies (as in the case of
the two aplastic anaemia patients in this study)
will mean that post-transfusion platelet
increments will be very poor.
Part II- Platelet Antigens
The frequency of the PLAT-negativity was found
to be absent in the 200 Chinese blood donors when
compared with the Caucasian populations. Thus, it is
believed that, analogous to the anti-D antibody in
the Rhesus haemolytic disease of the newborn, the
clinically important platelet-specific anti-PLA1
antibody is a very rare cause of alloimmune neonatal
thrombocytopenia and post-transfusion purpura in the
Hong Kong Chinese. The possible occurrence of these
two alloimmune thrombocytopenic disorders involving
platelet-specific antigens other than the PLA1, e-. g.
the Baka antigen cannot be excluded since 8% of the
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local Chinese population are Baka negative. However,
this seems to be unlikely based on the European and
American experiences on the involvement of Baka
incompatibility causing alloimmunization being rare.
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